Since deferoxamine B, when administered as a single daily intramuscular injection of 0.75 g, is unable to promote sufficient urinary iron excretion to achieve net negative iron balance in siderosis, we evaluated its administration as a constant infusion over 24 hours. We compared intravenous and subcutaneous routes in 24 siderotic patients who had excreted 420 to 630 mg (mean, 480 mg) of iron per month on intramuscular therapy. With the intravenous route urinary iron excretions increased to 570 to 3690 mg (mean, 1595 mg) per month. Constant subcutaneous delivery was 90 per cent as effective as intravenous administration on a dose-for-dose basis. Noteworthy net cumulative urinary iron excretions (urinary iron excretions minus transfused iron), often in excess of 1 g per month, have been maintained in all patients. Constant subcutaneous deferoxamine administration may prove to be an effective and practical means of eliminating large quantities of iron in siderosis.
This article has been cited by other articles:
Schwartz, K. A., Li, Z., Schwartz, D. E., Cooper, T. G., Braselton, W. E.
(2002). Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J. Appl. Physiol.
93: 746-751
[Abstract][Full Text]
Kushner, J. P., Porter, J. P., Olivieri, N. F.
(2001). Secondary Iron Overload. ASH Education Book
2001: 47-61
[Abstract][Full Text]
Franchini, M., Gandini, G., de Gironcoli, M., Vassanelli, A., Borgna-Pignatti, C., Aprili, G.
(2000). Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood
95: 2776-2779
[Abstract][Full Text]
Choudhury, R., Epemolu, R. O., Rai, B. L., Hider, R. C., Singh, S.
(1997). Metabolism and Pharmacokinetics of 1-(2'-Trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Drug Metab. Dispos.
25: 332-339
[Abstract][Full Text]
Olivieri, N. F., Brittenham, G. M.
(1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood
89: 739-761
[Full Text]
Allen, N.H.P., Burns, A.
(1995). The treatment of Alzheimer's disease. J Psychopharmacol
9: 43-56
Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W.
(1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM
331: 567-573
[Abstract][Full Text]
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R.
(1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM
331: 574-578
[Abstract][Full Text]
Maurer, H. S., Lloyd-Still, J. D., Ingrisano, C., Gonzalez-Crussi, F., Honig, G. R.
(1988). A Prospective Evaluation of Iron Chelation Therapy in Children With Severe {beta}-Thalassemia: A Six-Year Study. Arch Pediatr Adolesc Med
142: 287-292
[Abstract]
Oliver, D.
(1988). Syringe drivers in palliative care: a review. Palliat Med
2: 21-26
[Abstract]
Sklar, C. A., Lew, L. Q., Yoon, D. J., David, R.
(1987). Adrenal Function in Thalassemia Major Following Long-term Treatment With Multiple Transfusions and Chelation Therapy: Evidence for Dissociation of Cortisol and Adrenal Androgen Secretion. Arch Pediatr Adolesc Med
141: 327-330
[Abstract]
Grisaru, D., Goldfarb, A. W., Gotsman, M. S., Rachmilewitz, E. A., Hasin, Y.
(1986). Deferoxamine Improves Left Ventricular Function in {beta}-Thalassemia. Arch Intern Med
146: 2344-2349
[Abstract]
Schafer, A. I., Rabinowe, S., Le Boff, M. S., Bridges, K., Cheron, R. G., Dluhy, R.
(1985). Long-term Efficacy of Deferoxamine Iron Chelation Therapy in Adults With Acquired Transfusional Iron Overload. Arch Intern Med
145: 1217-1221
[Abstract]
Miller, D. H., Borer, J. S.
(1983). The Cardiomyopathies: A Pathophysiologic Approach to Therapeutic Management. Arch Intern Med
143: 2157-2162
[Abstract]
Miser, A. W., Davis, D. M., Hughes, C. S., Mulne, A. F., Miser, J. S.
(1983). Continuous Subcutaneous Infusion of Morphine in Children With Cancer. Arch Pediatr Adolesc Med
137: 383-385
[Abstract]
NIENHUIS, A. W., BENZ, E. J. Jr., PROPPER, R., CORASH, L., ANDERSON, W. F., HENRY, W., BORER, J.
(1979). Thalassemia Major: Molecular and Clinical Aspects. ANN INTERN MED
91: 883-897
[Abstract]
Sarnaik, S., Soorya, D., Kim, J., Ravindranath, Y., Lusher, J.
(1979). Periodic Transfusions for Sickle Cell Anemia and CNS Infarction. Arch Pediatr Adolesc Med
133: 1254-1257
[Abstract]
Young, N., Henry, W., Nienhuis, A. W.
(1979). Treatment of Primary Hemochromatosis With Deferoxamine. JAMA
241: 1152-1154
[Abstract]
Blume, K. G., Beutler, E., Chiller, R. K., Fahey, J. L., Sharkoff, D., Zia, P. K.
(1978). Continuous Intravenous Deferoxamine Infusion: Treatment of Secondary Hemochromatosis in Adults. JAMA
239: 2149-2151
[Abstract]
Crosby, W. H.
(1978). Hematology. JAMA
239: 515-517
Previous
